CompletedPhase 2NCT00001564
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
Studying Extraskeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Crystal L Mackall, M.D.National Cancer Institute (NCI)
- Intervention
- EF-1 Peptide(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 1996 – 2007
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00001564 on ClinicalTrials.gov